Ombudsman Probes Whether Industry Can Influence EMA In Pre-Submission Meetings

 
• By Vibha Sharma

The European Medicines Agency’s practice of holding pre-submission meetings with drug developers is being investigated by the European Ombudsman, who believes there is scope to make such interactions more transparent to tackle concerns over possible bias.

BIAS
EMA’s Pre-Submission Meetings Should Be More Transparent To Tackle Concerns Of Possible Bias • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards